Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Craneware revenue growth accelerates in first half
(Sharecast News) - Healthcare software specialist Craneware said in a trading update on Wednesday that it saw accelerated revenue growth in the six months ended 31 December, reflecting an improving market environment as US hospitals and healthcare institutions refocussed their strategic goals. The AIM-traded firm said revenue jumped 8% to $91m, aligning with its expectations.
Adjusted EBITDA also rose 8%, reaching around $27.5m, up from $25.5m in the first half of the 2023 financial year.
Despite sales success yet to be converted into revenue, annual recurring revenue (ARR) increased about 3% to $171.4m, as the company maintained a net revenue retention rate of 100%.
Craneware said it had continued to employ its cash reserves to reduce debt and interest costs, resulting in lower interest rate charges.
That, coupled with growth in the period, led to a return to growth in adjusted earnings per share, with a 3% increase, compared to the 6% decrease seen in the same period a year earlier.
The company said it maintained a robust financial position, with total bank debt reduced to $59.2m from $107.9m year-on-year, while total cash reserves slid to $63.9m from $90.8m.
Its board said it had decided to extend the share buyback programme, originally set to expire on 17 January, for an additional three months to 17 April under the same terms as previously announced.
Looking ahead, Craneware said its investments in the Trisus platform, as well as the recent launch of optimisation suites and innovative partnerships, positioned it strongly for the second half of the year.
The firm said it anticipated benefiting from growing confidence in its market, and saw substantial new opportunities to support its customers in delivering better value in US healthcare.
"With US healthcare and our hospital customers re-focusing on the future, the drive to better value in healthcare has returned to the forefront of their strategic priorities and we are pleased to see the returning confidence having a positive impact on our financial results," said chief executive officer Keith Neilson.
"The importance of digitalisation, to meet these challenges, has never been clearer.
"With approximately 40% of all US hospitals as customers, our considerable data assets and expanded offering allow us to derive meaningful insights for them to improve their operational efficiency, ensure their financial strength and continue to deliver outstanding care to their communities."
Craneware said it would release its results for the six months ended 31 December on 4 March.
At 1352 GMT, shares in Craneware were up 1.77% at 1,837p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.